Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Document first published:
Page updated:
Topic:
,
Publication type:

Obinutuzumab is not recommended to be available as a routine commissioning treatment option in refractory systemic lupus erythematosus.

The policy is restricted to adults and post-pubescent children, via the Medicines for Children policy.

Document

Clinical commissioning policy: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Clinical commissioning policy: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 169 KB
  • 6 pages

Summary

Published 19 January 2026.

Document

NHS England evidence review: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

NHS England evidence review: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 387 KB
  • 33 pages

Summary

Published 19 January 2026.

Document

Engagement report: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Engagement report: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 195 KB
  • 5 pages

Summary

Published 19 January 2026.

Document

Clinical Priorities Advisory Group summary report: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Clinical Priorities Advisory Group summary report: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 214 KB
  • 8 pages

Summary

Published 19 January 2026.

Document

Clinical panel report: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

Clinical panel report: Obinutuzumab for systemic lupus erythematosus with secondary non-response to rituximab (adults and post-pubescent children)

  • PDF
  • 128 KB
  • 2 pages

Summary

Published 19 January 2026.